EGFR and head and neck squamous cell carcinoma: EGFR expression and abnormal gene copy number were associated with a poor prognosis of HNSCC patients [9,10,11]; and the anti-EGFR antibody cetuximab has been approved for treating HNSCC [12,13,14,15].